BioMedNewsBreaks – Vivos Therapeutics Inc. Files Registration Statement for Proposed $20M Initial Public Offering

Vivos Therapeutics, a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, on Friday announced that is has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its common stock. According to the update, application has been made for listing the common stock on the Nasdaq Capital Market under the ticker symbol “VVOS.” The proposed $20,000,000 offering (not including the underwriters’ over-allotment option), which is subject to market conditions with no assurance as to its actual completion or terms, has a proposed price range of between $5.00 and $7.00 per share. Roth Capital Partners is acting as lead book-running manager and representative of the underwriters for the proposed offering. Craig-Hallum Capital Group and National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation (NASDAQ: NHLD), are acting as co-managers of the proposed offering.

To view the full press release, visit https://ibn.fm/3wFu3

About Vivos Therapeutics Inc.

Vivos Therapeutics is an emerging global leader in the treatment of obstructive sleep apnea (“OSA”), a debilitating condition affecting nearly 1 billion people worldwide. Headquartered in Denver, Colorado, the company utilizes proprietary, groundbreaking technology; a proven, go-to-market strategy; and a powerful executive team dedicated to changing the face of health care by helping people of all ages properly breathe and sleep. At the core of Vivos’ mission to eradicate OSA is the Vivos System(R), a revolutionary clinical breakthrough in the treatment of sleep apnea caused by craniofacial anatomy development. The Vivos System multidisciplinary treatment protocol involves collaboration between physicians, specially trained dentists who have completed advanced training in craniofacial sleep medicine, and other ancillary health-care providers. In support of its growth strategy, Vivos has established FDA-approved and registered manufacturing facilities in the United States, Canada and Asia. For more information, visit the company’s website at www.VivosLife.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork